ABSTRACT -Background -Insulin resistance and diabetes mellitus are common extrahepatic manifestations of chronic hepatitis C (HCV). Insulin resistance assessed by HOMA-IR is associated with low rates of sustained virological response, especially in HCV genotype 1 positive patients treated with peginterferon/ribavirin. The effect of insulin resistance on sustained virologic response in HCV genotype 3 positive patients who were treated with peginterferon/ribavirin still remains unclear. Objective -To evaluate the impact of insulin resistance on sustained virological response in HCV genotype 3 patients treated with peginterferon/ribavirin. Methods -A retrospective multicenter study was performed to evaluate the impact of insulin resistance on sustained virological response in non-diabetic HCV genotype 3 positive patients treated with peginterferon and ribavirin. A total of 200 HCV genotype 3 positive patients were enrolled in the study. All patients were non-diabetic. Each patient had a HOMA-IR value measured before the initiation of HCV treatment with peginterferon/ribavirin. The treatment duration was at least 24 weeks. The HOMA-IR cut-off was defined in the study as ≥2.5 due to the coefficient of correlation with sustained virological response of 0. 
INTRODUCTION
Insulin resistance (IR) and diabetes mellitus (DM) are common extrahepatic manifestations of chronic hepatitis C (HCV) (1) (2) (3) (4) (5) . The relationship between HCV and DM seems to be related to a direct effect of the HCV on the insulin signaling pathway (6) (7) (8) .
Insulin resistance assessed by HOMA-IR (Homeostatic model assessment) is associated with low rates of sustained virological response (SVR), especially in genotype 1 positive patients treated with peginterferon/ribavirin (PEG/RBV) (9) (10) (11) (12) . Prior studies have shown that the presence of IR, stratified by genotypes, had a negative effect on SVR rates in patients with genotype 2 or 3 as compared to genotype 1 positive patients [OR=4.45 (95% CI: 1.59-12.49) for genotypes 2, 3 vs OR=2.23 (95% CI: 1.59-3.13) for genotype 1]. (13) (14) (15) (16) (17) (18) (19) (20) . However, only four studies have assessed the impact of IR on SVR in genotype 3 positive patients alone with differing results (14, 15, 17, 18) . The prevalence of HCV genotype 3 worldwide is approximately 30% of global HCV infections and is highly prevalent in low-income regions (21) . The majority of these patients are likely to have faster fibrosis progression (22) and a higher risk of developing hepatocellular carcinoma (23) .
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Despite the advent of new highly effective interferon-free HCV therapies (24, 25) , there still remains concern for the optimal treatment for sub-groups of genotype 3 positive patients (26, 27) . In Latin American, Middle Eastern and African countries where the cost of drugs plays a significant role in available HCV treatment options, PEG/ RBV with or without sofosbuvir still remains a feasible treatment option (28, 29) . Therefore, it is still important to understand factors associated with low SVR rates to interferon-based treatment in genotype 3 positive patients alone.
Thus far, the majority of studies that have investigated predictors of SVR on the interferon-based therapies have grouped genotype 3 with genotype 2. To better understand predictors of SVR, especially IR, in genotype 3 patients, we retrospectively studied treatment-naïve patients exclusively infected with HCV genotype 3 who underwent treatment with peginterferon plus ribavirin for at least 24 weeks. The centers included in this study have HCV treatment experience and routinely require fasting insulin and glucose levels prior to initiating HCV therapy. Patients who were HCV genotype 3 positive and received antiviral treatment from 2010 to 2015 were included in this study. All patients were adults with age ≥18 years and whose first treatment regimen was peginterferon and ribavirin (PEG/RBV) for chronic HCV. Fasting insulin and glucose level were measured at least 3 months before initiating HCV therapy, and liver biopsies were taken up to 6 months prior treatment initiation. Patients were treated with weekly peginterferon alpha-2a or alpha 2b with ribavirin for at least 24 weeks. Pegylated interferon alpha-2a dose was 180 μg and peginterferon alfa 2b dose was 1.5 μg/kg of body weight. Ribavirin doses were 1000 mg/d in patients ≤75kg and 1200 mg/d in patients >75kg (30) . Exclusion criteria included alcohol intake greater than 20 g/d, a previous diagnosis of diabetes mellitus and the use of oral diabetic medications specifically insulin sensitizers and insulin production simulators. Coinfection with hepatitis B virus or HIV (human immunodeficiency virus) and other liver disease besides hepatitis C, except for NAFLD (nonalcoholic fatty liver disease), were excluded.
METHODS

Pretreatment characteristics
Demographics measured included age, gender, and body mass index (BMI -kg/m 2 ). Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and gammaglutamyl transpeptidase (GGT), platelets count (mm 3 /mL), total cholesterol, HDL-c, LDL-c, triglycerides, and glucose were assessed by automated methods. Insulin serum levels were determined by chemiluminescence. Insulin resistance was determined by HOMA-IR where HOMA-Ir is calculated as fasting glucose (mg/dL) multiplied by fasting insulin (IU/mL) divided by 405 (31) . Serum HCV-RNA levels were quantified at the beginning of treatment using quantitative reverse-transcription polymerase chain reaction (PCR) (Cobas Amplicor Test -Roche Diagnostic System, USA). For statistical purposes we chose 400,000 IU/mL as the cut-off value to separate low (<400,000 IU/mL) from high (≥400,000 IU/mL) viral load. Sustained virological response was defined as undetectable HCV-RNA levels achieved at 24 weeks after treatment completion.
HCV genotyping was performed by sequencing of the HCV 5' non-coding segment (5´UTR). AST, ALT, GGT, and alkaline phosphatase were analyzed as times of upper limit of normalization (ULN). Lipid panel was defined as total cholesterol level (mg/dL), HDL cholesterol (mg/dL) and triglycerides (mg/dL).
Liver biopsies were obtained up to 6 months prior treatment. Fibrosis and Activity scores were classified based on Metavir system (32) . Patients were divided into two groups according to fibrosis stage: patients with no fibrosis to significant fibrosis (F0-F2); and patients with advanced fibrosis (F3 and F4). Activity score was categorized as mild (A0, A1) or moderate/severe (A2, A3). Hepatic steatosis was scored as the percentage of hepatocytes containing macrovesicular fat droplets and was graded from 0 to 3 (grade 0, <5% steatosis, grade 1, 5%-33% hepatocytes affected; grade 2, 33%-66% of hepatocytes affected; grade 3, 67% or more of hepatocytes affected).
This study was performed according to the principles of the Declaration of Helsinki and was approved by the Ethical Institutional Review Board.
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) and categorical variables as presented as frequency and percentage. The t-test was used to compare continuous variables and the Chi-square or Fisher's test was used for categorical variables. The Spearman correlation was used to identify the cut-offs of HOMA-IR associated with SVR. To identify the independent predictors of SVR, we used a logistic regression model for variables that showed a level of significance less than 0.05 in univariate analysis. Tests were two-sided, and significance was accepted at P<0.05. All analyses were performed with Stata ® 14 (StataCorp, College Station, TX).
RESULTS
A total of 200 genotype 3 positive patients were included in this study. Patients' baseline demographic, clinical and virological characteristics are showed in TABLE 1. The percentage of male's subjects was 58% and the mean age was 48.1±9.4 years. The mean BMI was 26.39±4.7 kg/m 2 and mean HOMA-IR was 3.02±2. Gender, ALT, GGT, lipid panel, viral load, BMI, presence of steatosis and inflammatory activity were not found to be significantly associated with SVR.
DISCUSSION
In HCV genotype 3 positive patients who are treated with PEG/RBV, several demographics, biochemical, virological and histological factors have been associated with SVR. In three large studies, it was found that viral load, age, weight, BMI and advanced fibrosis were the most important pretreatment predictors of SVR in genotype 3 positive patients who received Peg/RBV treatment (33) (34) (35) . However, these studies did not assess the effect of IR on SVR.
This study confirms previous reports that age and advanced fibrosis are predictors of SVR in genotype 3 positive patients (36, 37) . For every 6-year increment of age, we found that the likelihood of SVR decreased by 6%. It has been postulated that older HCVinfected patients have decreased rates of SVR to interferon-based therapies because they have higher rates of comorbidities, decreased treatment tolerance, and increased adverse events from antiviral treatment. Older infected patients also have had HCV longer allowing for more extensive liver damage compared to younger patients (38, 39) . In this study, patients with advanced fibrosis were older than those with mild or absent fibrosis (51 years for those with advanced fibrosis versus 45.7 years old for those with mild or absent fibrosis, P<0.0001).
In HCV genotype 3 positive patients who had bridging fibrosis and cirrhosis, the likelihood of achieving SVR was reduced by two fold compared to patients with mild or no fibrosis (F0-F2). This finding supports previous studies which also showed that the presence of advanced fibrosis is a negative predictive factor of SVR in genotype 3 patients (31) (32) (33) (40) (41) (42) (43) . This is the first study to assess the impact of IR on SVR in 200 HCV genotype 3 patients treated with PEG/RBV. Prior studies have tried to understand this effect but they grouped genotype 2 and genotype 3 together in analysis preventing the ability to determine effects of IR on HCV genotype 3 alone (19, 20) . In addition, a majority of previous studies had small samples sizes with contradictory results precluding any conclusion (15, 17, 18) . Fatovichi et al. showed that IR was a predictor of rapid virological response (RVR), but BMI was the only factor associated with SVR (14) . On the other hand, Eslam et al. studied 48 genotype 3 patients and found that IR was a significant predictor of early and late viral kinetics, and that IR was a negative predictor of SVR mentioned only in univariate analysis (15) . In this study, we did not explore the relationship between RVR and IR as RVR determination is not mandatory in Brazilian guidelines (30) . IR was assessed in our study using HOMA-IR, which has been shown to be correlated closely with the hyperinsulinemic euglycemic clamp technique (44) . Since there is no absolute cut-off value for HOMA-IR to diagnose IR in HCV patients, we established our cut-off value to be 2.5 due to the coefficient of correlation with SVR of rS= 0.202 (P=0.004). In this study, 56.5% of patients had HOMA-RI≥2.5 and they were older compared to those without IR (50.5 years for patients with IR versus 44.9 years for those without IR, P<0.0001).
Some studies have shown that the presence of parameters associated with IR such as DM and metabolic syndrome can also affect SVR rates. Shoeb D et al. estimated that the likelihood of SVR from PEG/RBV was reduced by 62% among HCV genotype 3 patients with DM (36) . Aziz et al. showed that HCV genotype 3 positive patients without metabolic syndrome who were treated with interferon based therapy had higher SVR rates compared to patients with metabolic syndrome (72.2% vs 43.7% P<0.05) (45) . However, they included diabetic patients in their analysis. Our study aimed to examine the effects of IR on SVR rates in patients with IR but not DM.
In this study, the univariate analysis showed that in patients with HOMA-IR≥2.5, the likelihood of achieving SVR was reduced by 2.6 fold compared to patients with HOMA-IR<2.5 [OR=2.630 (95%CI: 1.336-5.175) P=0.005]. Age and advanced fibrosis were the only negative predictors of SVR in multivariate analysis. A sub-analysis per center was also done and no significant differences in the effect of IR on SVR were seen (data not showed). IR as predictive value for SVR founded in the univariate analysis merely reflects its relationship with age and degree of fibrosis which were seen as independent predictors of SVR in our patients. Thompson et al. showed that HCV genotype 3 positive patients who achieved SVR did not have a significant reduction in mean of HOMA-IR after treatment, which suggests that different factors could be involved with IR in patients with genotype 3 (46) . In this study, the factors associated with HOMA-IR≥2. 5 As this was a retrospective study, data for steatosis and HCV RNA levels was limited, only 81% and 78 % of the patients had information on the degree of steatosis and HCV-RNA levels, respectively. Lack of data could explain why either steatosis or HCV RNA levels did not reach significance. However, in prior studies, there is no clear consensus regarding the relationship between steatosis and SVR in genotype 3 positive patients (33) (34) (35) 47) . On the other hand, HCV viral load has been previously shown to be associated with SVR (33) (34) (35) . Even after changing the HCV-RNA cut-off value to 8000.000U I/L in our analysis, HCV-RNA levels still did not reach significance as a predictor of SVR in our study.
Our findings show that IR when measured by HOMA-IR, does not play a role in achieving SVR in non-diabetic patients with HCV genotype 3 who are treated with PEG/RBV. Despite the increased use of new interferon-free HCV therapies, interferon-based therapies still play a role in treating cirrhotic and previously-treated genotype 3 positive patients (33, 48) , and remain as a viable option for treating genotype 3 patients in Latin American, Africa and Middle West countries (34) .
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